WAT Waters Corporation

FY2025 10-K
Filed: Feb 23, 2026
Health Care
Laboratory Analytical InstrumentsSEC EDGAR

Waters Corporation (WAT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 23, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • Core business: Designs, manufactures, sells, and services LC, MS, and thermal analysis instruments, consumables, and software for life, materials, and food sciences
  • Transformative acquisition: Completed $16.8B BDS Business (BD Biosciences & Diagnostic Solutions) acquisition Feb 2026 via Reverse Morris Trust; BD shareholders received ~39.2% of combined company; reorganized into four segments
+3 more insights

Management Discussion & Analysis

  • Revenue $3.17B, up 7% YoY; Waters segment $2.81B (+8%), TA segment $352M (-1%)
  • Operating margin 25.4% vs 27.9% in 2024; $82M BDS acquisition costs and $20M ERP expenses weighed on 2025
+2 more insights

Risk Factors

  • $4.0B debt assumed via BDS Business Acquisition ($3.5B tranche due Feb 2027, $500M due Feb 2028); planned refinancing creates near-term capital market dependency
  • ~69% of net sales outside U.S.; U.S. Supreme Court Feb 2026 ruling invalidated IEEPA tariffs, creating cost structure and supply chain planning uncertainty
+3 more insights

Financial Summary
XBRL

Revenue

$3.2B

Net Income

$643M

Operating Margin

25.4%

Net Margin

20.3%

ROE

25.1%

Total Assets

$5.1B

EPS (Diluted)

$10.76

Operating Cash Flow

$653M

Source: XBRL data from Waters Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.

Other Waters Corporation Annual Reports

Get deeper insights on Waters Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available